JP2017537125A - 疾患および状態を処置するための組成物および方法 - Google Patents
疾患および状態を処置するための組成物および方法 Download PDFInfo
- Publication number
- JP2017537125A JP2017537125A JP2017530689A JP2017530689A JP2017537125A JP 2017537125 A JP2017537125 A JP 2017537125A JP 2017530689 A JP2017530689 A JP 2017530689A JP 2017530689 A JP2017530689 A JP 2017530689A JP 2017537125 A JP2017537125 A JP 2017537125A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- compound
- disease
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims description 59
- 238000000034 method Methods 0.000 title claims description 54
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 48
- 201000010099 disease Diseases 0.000 title claims description 45
- 239000000651 prodrug Substances 0.000 claims abstract description 96
- 229940002612 prodrug Drugs 0.000 claims abstract description 96
- 150000003839 salts Chemical class 0.000 claims abstract description 94
- 150000002148 esters Chemical class 0.000 claims abstract description 90
- 239000012453 solvate Substances 0.000 claims abstract description 75
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 37
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims description 244
- 125000000217 alkyl group Chemical group 0.000 claims description 216
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 60
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 55
- 229910052736 halogen Inorganic materials 0.000 claims description 51
- 150000002367 halogens Chemical class 0.000 claims description 50
- 239000008194 pharmaceutical composition Substances 0.000 claims description 48
- 125000003342 alkenyl group Chemical group 0.000 claims description 42
- 125000000304 alkynyl group Chemical group 0.000 claims description 42
- 125000003545 alkoxy group Chemical group 0.000 claims description 39
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- 125000003118 aryl group Chemical group 0.000 claims description 33
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 32
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 150000001412 amines Chemical class 0.000 claims description 27
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 25
- 125000003282 alkyl amino group Chemical group 0.000 claims description 25
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 22
- 102000004127 Cytokines Human genes 0.000 claims description 22
- 108090000695 Cytokines Proteins 0.000 claims description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 17
- 230000006378 damage Effects 0.000 claims description 17
- 206010061218 Inflammation Diseases 0.000 claims description 16
- 229910052731 fluorine Inorganic materials 0.000 claims description 16
- 230000004054 inflammatory process Effects 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 16
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 15
- 239000011737 fluorine Substances 0.000 claims description 15
- 208000027418 Wounds and injury Diseases 0.000 claims description 14
- 208000014674 injury Diseases 0.000 claims description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 12
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 12
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 12
- 206010035664 Pneumonia Diseases 0.000 claims description 11
- 206010006451 bronchitis Diseases 0.000 claims description 11
- 102100026078 F-box only protein 3 Human genes 0.000 claims description 10
- 101000913305 Homo sapiens F-box only protein 3 Proteins 0.000 claims description 10
- 230000001154 acute effect Effects 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 10
- 229940121354 immunomodulator Drugs 0.000 claims description 9
- 208000027866 inflammatory disease Diseases 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims description 8
- 230000002137 anti-vascular effect Effects 0.000 claims description 8
- 239000004599 antimicrobial Substances 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 239000003443 antiviral agent Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 8
- 239000007884 disintegrant Substances 0.000 claims description 8
- 239000003102 growth factor Substances 0.000 claims description 8
- 239000003018 immunosuppressive agent Substances 0.000 claims description 8
- 206010022000 influenza Diseases 0.000 claims description 8
- 239000011159 matrix material Substances 0.000 claims description 8
- 150000003180 prostaglandins Chemical class 0.000 claims description 8
- 239000000375 suspending agent Substances 0.000 claims description 8
- 229940122142 Lipoxygenase inhibitor Drugs 0.000 claims description 7
- 239000000654 additive Substances 0.000 claims description 7
- 238000007906 compression Methods 0.000 claims description 7
- 230000006835 compression Effects 0.000 claims description 7
- 239000000430 cytokine receptor antagonist Substances 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 230000003463 hyperproliferative effect Effects 0.000 claims description 7
- 239000002955 immunomodulating agent Substances 0.000 claims description 7
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims description 7
- 230000000241 respiratory effect Effects 0.000 claims description 7
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 235000013355 food flavoring agent Nutrition 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- 210000004072 lung Anatomy 0.000 claims description 6
- 239000003607 modifier Substances 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 5
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 206010030113 Oedema Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 208000007451 chronic bronchitis Diseases 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 230000002584 immunomodulator Effects 0.000 claims description 5
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 5
- 230000001861 immunosuppressant effect Effects 0.000 claims description 5
- 239000007928 intraperitoneal injection Substances 0.000 claims description 5
- 208000008423 pleurisy Diseases 0.000 claims description 5
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 5
- 239000007929 subcutaneous injection Substances 0.000 claims description 5
- 238000010254 subcutaneous injection Methods 0.000 claims description 5
- 231100000331 toxic Toxicity 0.000 claims description 5
- 230000002588 toxic effect Effects 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 241001420836 Ophthalmitis Species 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 206010047115 Vasculitis Diseases 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 206010009887 colitis Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 208000010403 panophthalmitis Diseases 0.000 claims description 4
- 229920005862 polyol Polymers 0.000 claims description 4
- 150000003077 polyols Chemical class 0.000 claims description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 4
- 239000008158 vegetable oil Substances 0.000 claims description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
- 206010006448 Bronchiolitis Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 206010014561 Emphysema Diseases 0.000 claims description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 206010069351 acute lung injury Diseases 0.000 claims description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 201000009267 bronchiectasis Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 238000002513 implantation Methods 0.000 claims description 3
- 238000010253 intravenous injection Methods 0.000 claims description 3
- 239000010466 nut oil Substances 0.000 claims description 3
- 235000019488 nut oil Nutrition 0.000 claims description 3
- 230000000414 obstructive effect Effects 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010006811 Bursitis Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010010741 Conjunctivitis Diseases 0.000 claims description 2
- 206010015943 Eye inflammation Diseases 0.000 claims description 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010051604 Lung transplant rejection Diseases 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- 208000000112 Myalgia Diseases 0.000 claims description 2
- 208000009525 Myocarditis Diseases 0.000 claims description 2
- 208000005141 Otitis Diseases 0.000 claims description 2
- 206010035742 Pneumonitis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 206010037765 Radiation pneumonitis Diseases 0.000 claims description 2
- 208000025747 Rheumatic disease Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 2
- 201000003278 cryoglobulinemia Diseases 0.000 claims description 2
- 201000003146 cystitis Diseases 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims description 2
- 201000004792 malaria Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 206010033072 otitis externa Diseases 0.000 claims description 2
- 208000008494 pericarditis Diseases 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 201000007094 prostatitis Diseases 0.000 claims description 2
- 230000000552 rheumatic effect Effects 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims description 2
- 206010043207 temporal arteritis Diseases 0.000 claims description 2
- 230000005784 autoimmunity Effects 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 150000002222 fluorine compounds Chemical class 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract description 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 1
- 235000002639 sodium chloride Nutrition 0.000 description 86
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 72
- -1 RANK Proteins 0.000 description 63
- 239000000243 solution Substances 0.000 description 38
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- 239000002904 solvent Substances 0.000 description 33
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 32
- 239000000543 intermediate Substances 0.000 description 32
- 125000000753 cycloalkyl group Chemical group 0.000 description 30
- 239000007787 solid Substances 0.000 description 29
- 150000003335 secondary amines Chemical class 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 21
- 239000003921 oil Substances 0.000 description 20
- 235000019198 oils Nutrition 0.000 description 19
- 238000003786 synthesis reaction Methods 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 17
- 150000004677 hydrates Chemical class 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 17
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 16
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 16
- 239000012279 sodium borohydride Substances 0.000 description 16
- 229910000033 sodium borohydride Inorganic materials 0.000 description 16
- 125000001424 substituent group Chemical group 0.000 description 16
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 15
- 239000002253 acid Substances 0.000 description 14
- 125000005842 heteroatom Chemical group 0.000 description 14
- 239000002262 Schiff base Substances 0.000 description 13
- 150000004753 Schiff bases Chemical class 0.000 description 13
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 13
- 239000003826 tablet Substances 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- 150000003512 tertiary amines Chemical class 0.000 description 11
- 238000012384 transportation and delivery Methods 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 10
- 238000002390 rotary evaporation Methods 0.000 description 10
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 229960000583 acetic acid Drugs 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 125000003710 aryl alkyl group Chemical group 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 150000001408 amides Chemical class 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 125000004438 haloalkoxy group Chemical group 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 108010080432 Tumor Necrosis Factor Receptor-Associated Peptides and Proteins Proteins 0.000 description 6
- 102000000160 Tumor Necrosis Factor Receptor-Associated Peptides and Proteins Human genes 0.000 description 6
- 108090000848 Ubiquitin Proteins 0.000 description 6
- 102000044159 Ubiquitin Human genes 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical compound C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 6
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 6
- 125000001188 haloalkyl group Chemical group 0.000 description 6
- 125000002883 imidazolyl group Chemical group 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 6
- 125000003226 pyrazolyl group Chemical group 0.000 description 6
- 125000004076 pyridyl group Chemical group 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 102100037309 F-box/LRR-repeat protein 2 Human genes 0.000 description 5
- 101001026881 Homo sapiens F-box/LRR-repeat protein 2 Proteins 0.000 description 5
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 5
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 239000012362 glacial acetic acid Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 125000001715 oxadiazolyl group Chemical group 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 4
- LPODYMQVWOTQDO-UHFFFAOYSA-N 1-[4-(1,3-oxazol-5-yl)phenyl]butane-2,3-diamine Chemical compound CC(N)C(N)CC1=CC=C(C=C1)C1=CN=CO1 LPODYMQVWOTQDO-UHFFFAOYSA-N 0.000 description 4
- JTHOFIPAJDVQLC-UHFFFAOYSA-N 3-(3-fluoro-4-pyrimidin-2-ylphenyl)-1-N-[(3-fluoro-4-pyrimidin-2-ylphenyl)methyl]propane-1,2-diamine Chemical compound FC=1C=C(CC(CNCC2=CC(=C(C=C2)C2=NC=CC=N2)F)N)C=CC=1C1=NC=CC=N1 JTHOFIPAJDVQLC-UHFFFAOYSA-N 0.000 description 4
- JUYLMPWKVWDXBE-UHFFFAOYSA-N 4-pyrimidin-2-ylbenzaldehyde Chemical compound C1=CC(C=O)=CC=C1C1=NC=CC=N1 JUYLMPWKVWDXBE-UHFFFAOYSA-N 0.000 description 4
- 108010066805 F-Box Proteins Proteins 0.000 description 4
- 102000018700 F-Box Proteins Human genes 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 4
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 125000005907 alkyl ester group Chemical group 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 229940124630 bronchodilator Drugs 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
- 238000011260 co-administration Methods 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 206010052015 cytokine release syndrome Diseases 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 125000003838 furazanyl group Chemical group 0.000 description 4
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 125000002636 imidazolinyl group Chemical group 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 125000001786 isothiazolyl group Chemical group 0.000 description 4
- 125000000842 isoxazolyl group Chemical group 0.000 description 4
- 235000011090 malic acid Nutrition 0.000 description 4
- 125000002757 morpholinyl group Chemical group 0.000 description 4
- 235000019371 penicillin G benzathine Nutrition 0.000 description 4
- PQPFFKCJENSZKL-UHFFFAOYSA-N pentan-3-amine Chemical compound CCC(N)CC PQPFFKCJENSZKL-UHFFFAOYSA-N 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 239000003380 propellant Substances 0.000 description 4
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 4
- 125000002755 pyrazolinyl group Chemical group 0.000 description 4
- 125000002098 pyridazinyl group Chemical group 0.000 description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 4
- 125000001422 pyrrolinyl group Chemical group 0.000 description 4
- 125000000168 pyrrolyl group Chemical group 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000008247 solid mixture Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 125000003831 tetrazolyl group Chemical group 0.000 description 4
- PTEWRXNORXIYSV-HNNXBMFYSA-N (2S)-2-N-[[2-fluoro-4-(5-fluoropyrimidin-2-yl)phenyl]methyl]-1-N-[[4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]methyl]propane-1,2-diamine Chemical compound C[C@@H](CNCC1=CC=C(C=C1)C1=NN=C(C)O1)NCC1=C(F)C=C(C=C1)C1=NC=C(F)C=N1 PTEWRXNORXIYSV-HNNXBMFYSA-N 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 3
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 3
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 206010050685 Cytokine storm Diseases 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000021642 Muscular disease Diseases 0.000 description 3
- 201000009623 Myopathy Diseases 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- 108091007047 SCF complex Proteins 0.000 description 3
- 102000036366 SCF complex Human genes 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 102000002689 Toll-like receptor Human genes 0.000 description 3
- 108020000411 Toll-like receptor Proteins 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000004423 acyloxy group Chemical group 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000005441 aurora Substances 0.000 description 3
- 238000007664 blowing Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 125000005303 dithiazolyl group Chemical group S1SNC(=C1)* 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 229940125721 immunosuppressive agent Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 229960000448 lactic acid Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 239000011976 maleic acid Substances 0.000 description 3
- 239000001630 malic acid Substances 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Chemical group 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 208000023504 respiratory system disease Diseases 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000001113 thiadiazolyl group Chemical group 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 125000004306 triazinyl group Chemical group 0.000 description 3
- 125000001425 triazolyl group Chemical group 0.000 description 3
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 3
- 238000003828 vacuum filtration Methods 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 2
- OAEJODVYVOAOPH-UHFFFAOYSA-N (2-fluoro-4-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=C(C=O)C=C1F OAEJODVYVOAOPH-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- ICBKXGJJJQTUAY-VIFPVBQESA-N (4S)-nonan-4-amine Chemical compound CCCCC[C@@H](N)CCC ICBKXGJJJQTUAY-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 2
- AGYUQBNABXVWMS-UHFFFAOYSA-N 2-chloro-5-fluoropyrimidine Chemical compound FC1=CN=C(Cl)N=C1 AGYUQBNABXVWMS-UHFFFAOYSA-N 0.000 description 2
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 2
- YGCZTXZTJXYWCO-UHFFFAOYSA-N 3-phenylpropanal Chemical compound O=CCCC1=CC=CC=C1 YGCZTXZTJXYWCO-UHFFFAOYSA-N 0.000 description 2
- PZSMUPGANZGPBF-UHFFFAOYSA-N 4-[5-(dithiolan-3-yl)pentanoylamino]butanoic acid Chemical compound OC(=O)CCCNC(=O)CCCCC1CCSS1 PZSMUPGANZGPBF-UHFFFAOYSA-N 0.000 description 2
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 2
- 102000006312 Cyclin D2 Human genes 0.000 description 2
- 108010058544 Cyclin D2 Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000004479 aerosol dispenser Substances 0.000 description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- 229960003060 bambuterol Drugs 0.000 description 2
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 description 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 2
- 229940092705 beclomethasone Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- 229940124748 beta 2 agonist Drugs 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- 229960004436 budesonide Drugs 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000004452 carbocyclyl group Chemical group 0.000 description 2
- 125000002915 carbonyl group Chemical class [*:2]C([*:1])=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 229960003728 ciclesonide Drugs 0.000 description 2
- 229960001117 clenbuterol Drugs 0.000 description 2
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229960002179 ephedrine Drugs 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 229960001022 fenoterol Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229960002848 formoterol Drugs 0.000 description 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 229960002598 fumaric acid Drugs 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- SRMHHEPXZLWKOK-UHFFFAOYSA-N heptan-3-amine Chemical compound CCCCC(N)CC SRMHHEPXZLWKOK-UHFFFAOYSA-N 0.000 description 2
- CLJMMQGDJNYDER-UHFFFAOYSA-N heptan-4-amine Chemical compound CCCC(N)CCC CLJMMQGDJNYDER-UHFFFAOYSA-N 0.000 description 2
- WGBBUURBHXLGFM-UHFFFAOYSA-N hexan-2-amine Chemical compound CCCCC(C)N WGBBUURBHXLGFM-UHFFFAOYSA-N 0.000 description 2
- HQLZFBUAULNEGP-UHFFFAOYSA-N hexan-3-amine Chemical compound CCCC(N)CC HQLZFBUAULNEGP-UHFFFAOYSA-N 0.000 description 2
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000012642 immune effector Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229960004078 indacaterol Drugs 0.000 description 2
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004901 leucine-rich repeat Anatomy 0.000 description 2
- 229950008204 levosalbutamol Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 229940125389 long-acting beta agonist Drugs 0.000 description 2
- 231100000516 lung damage Toxicity 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940098895 maleic acid Drugs 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 239000002088 nanocapsule Substances 0.000 description 2
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 2
- 229960004398 nedocromil Drugs 0.000 description 2
- YRJCXPFMFZIXRI-UHFFFAOYSA-N nonan-3-amine Chemical compound CCCCCCC(N)CC YRJCXPFMFZIXRI-UHFFFAOYSA-N 0.000 description 2
- BKEVGGILGWUWSB-UHFFFAOYSA-N nonan-5-amine Chemical compound CCCCC(N)CCCC BKEVGGILGWUWSB-UHFFFAOYSA-N 0.000 description 2
- JASMWYNKLTULAN-UHFFFAOYSA-N octan-3-amine Chemical compound CCCCCC(N)CC JASMWYNKLTULAN-UHFFFAOYSA-N 0.000 description 2
- PSBKYMODPYHLAW-UHFFFAOYSA-N octan-4-amine Chemical compound CCCCC(N)CCC PSBKYMODPYHLAW-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229960002657 orciprenaline Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- IGEIPFLJVCPEKU-UHFFFAOYSA-N pentan-2-amine Chemical compound CCCC(C)N IGEIPFLJVCPEKU-UHFFFAOYSA-N 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- DTUQWGWMVIHBKE-UHFFFAOYSA-N phenylacetaldehyde Chemical compound O=CCC1=CC=CC=C1 DTUQWGWMVIHBKE-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229960002052 salbutamol Drugs 0.000 description 2
- 229960004017 salmeterol Drugs 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 229960005137 succinic acid Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 125000000475 sulfinyl group Chemical class [*:2]S([*:1])=O 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 229960000195 terbutaline Drugs 0.000 description 2
- UYNSYFDLTSSUNI-LURJTMIESA-N tert-butyl n-[(2s)-2-aminopropyl]carbamate Chemical compound C[C@H](N)CNC(=O)OC(C)(C)C UYNSYFDLTSSUNI-LURJTMIESA-N 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 2
- 229940110309 tiotropium Drugs 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- VSRBKQFNFZQRBM-UHFFFAOYSA-N tuaminoheptane Chemical compound CCCCCC(C)N VSRBKQFNFZQRBM-UHFFFAOYSA-N 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- XDWJUKGYXFRXLD-SNVBAGLBSA-N (2R)-3,3,3-trifluoro-1-N-[[4-(1,3,4-oxadiazol-2-yl)phenyl]methyl]propane-1,2-diamine Chemical compound N[C@H](CNCC1=CC=C(C=C1)C1=NN=CO1)C(F)(F)F XDWJUKGYXFRXLD-SNVBAGLBSA-N 0.000 description 1
- IZFBCFVIQPFEDP-VIFPVBQESA-N (2S)-2-N-[[2-fluoro-4-(5-fluoropyrimidin-2-yl)phenyl]methyl]propane-1,2-diamine Chemical compound C[C@@H](CN)NCC1=C(F)C=C(C=C1)C1=NC=C(F)C=N1 IZFBCFVIQPFEDP-VIFPVBQESA-N 0.000 description 1
- PQAGDYAZUAYVPE-HSHFZTNMSA-N (2r)-3,3,3-trifluoropropane-1,2-diamine;hydrochloride Chemical compound Cl.NC[C@@H](N)C(F)(F)F PQAGDYAZUAYVPE-HSHFZTNMSA-N 0.000 description 1
- AEIAMRMQKCPGJR-HWYNEVGZSA-N (2r)-propane-1,2-diamine;dihydrochloride Chemical compound Cl.Cl.C[C@@H](N)CN AEIAMRMQKCPGJR-HWYNEVGZSA-N 0.000 description 1
- AEIAMRMQKCPGJR-QTNFYWBSSA-N (2s)-propane-1,2-diamine;dihydrochloride Chemical compound Cl.Cl.C[C@H](N)CN AEIAMRMQKCPGJR-QTNFYWBSSA-N 0.000 description 1
- BRLVXFONMZRJCD-UHFFFAOYSA-N (3-azaniumyl-2,3-dimethylbutan-2-yl)azanium;dichloride Chemical compound Cl.Cl.CC(C)(N)C(C)(C)N BRLVXFONMZRJCD-UHFFFAOYSA-N 0.000 description 1
- VXWBQOJISHAKKM-UHFFFAOYSA-N (4-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=C(C=O)C=C1 VXWBQOJISHAKKM-UHFFFAOYSA-N 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- OPCJOXGBLDJWRM-UHFFFAOYSA-N 1,2-diamino-2-methylpropane Chemical compound CC(C)(N)CN OPCJOXGBLDJWRM-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- PPNCOQHHSGMKGI-UHFFFAOYSA-N 1-cyclononyldiazonane Chemical compound C1CCCCCCCC1N1NCCCCCCC1 PPNCOQHHSGMKGI-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 1
- ROTSHDPXWSQOBF-UHFFFAOYSA-N 2-fluoro-4-(5-fluoropyrimidin-2-yl)benzaldehyde Chemical compound FC1=C(C=O)C=CC(=C1)C1=NC=C(C=N1)F ROTSHDPXWSQOBF-UHFFFAOYSA-N 0.000 description 1
- UPCCKZGEKVVLHM-UHFFFAOYSA-N 2-fluoro-4-pyrimidin-2-ylbenzaldehyde Chemical compound C1=C(C=O)C(F)=CC(C=2N=CC=CN=2)=C1 UPCCKZGEKVVLHM-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- KJMKROLYLRRJDN-UHFFFAOYSA-N 2-pyrrolidin-1-ylpyrimidine-5-carbaldehyde Chemical compound N1=CC(C=O)=CN=C1N1CCCC1 KJMKROLYLRRJDN-UHFFFAOYSA-N 0.000 description 1
- CUXSFHYUQYJLLU-UHFFFAOYSA-N 3-(3-fluoro-4-pyrimidin-2-ylphenyl)prop-2-ene-1,2-diamine Chemical compound FC=1C=C(C=C(CN)N)C=CC=1C1=NC=CC=N1 CUXSFHYUQYJLLU-UHFFFAOYSA-N 0.000 description 1
- WADSJYLPJPTMLN-UHFFFAOYSA-N 3-(cycloundecen-1-yl)-1,2-diazacycloundec-2-ene Chemical compound C1CCCCCCCCC=C1C1=NNCCCCCCCC1 WADSJYLPJPTMLN-UHFFFAOYSA-N 0.000 description 1
- PZQDAKKBCZMUTR-UHFFFAOYSA-N 4-(1,3,4-oxadiazol-2-yl)benzaldehyde Chemical compound C1=CC(C=O)=CC=C1C1=NN=CO1 PZQDAKKBCZMUTR-UHFFFAOYSA-N 0.000 description 1
- GDXLZBAOBKGCEK-UHFFFAOYSA-N 4-(1,3-oxazol-5-yl)benzaldehyde Chemical compound C1=CC(C=O)=CC=C1C1=CN=CO1 GDXLZBAOBKGCEK-UHFFFAOYSA-N 0.000 description 1
- PMFVNGSYJAIEPJ-UHFFFAOYSA-N 4-(4-methyl-1,3-oxazol-5-yl)benzaldehyde Chemical compound N1=COC(C=2C=CC(C=O)=CC=2)=C1C PMFVNGSYJAIEPJ-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- NHFRGTVSKOPUBK-UHFFFAOYSA-N 4-phenylbutanal Chemical group O=CCCCC1=CC=CC=C1 NHFRGTVSKOPUBK-UHFFFAOYSA-N 0.000 description 1
- XDTDWMVEIFYQPO-UHFFFAOYSA-N 5-(1,3,4-oxadiazol-2-yl)pyridine-2-carbaldehyde Chemical compound O1C(=NN=C1)C=1C=CC(=NC=1)C=O XDTDWMVEIFYQPO-UHFFFAOYSA-N 0.000 description 1
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010006417 Bronchial carcinoma Diseases 0.000 description 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 1
- 101710098272 C-X-C motif chemokine 11 Proteins 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 102100024816 E3 ubiquitin-protein ligase TRAF7 Human genes 0.000 description 1
- 108700033932 EC 6.2.1.45 Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 101000830899 Homo sapiens E3 ubiquitin-protein ligase TRAF7 Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- ONXPDKGXOOORHB-BYPYZUCNSA-N N(5)-methyl-L-glutamine Chemical compound CNC(=O)CC[C@H](N)C(O)=O ONXPDKGXOOORHB-BYPYZUCNSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- ZTUPEBIWNAMBGP-UHFFFAOYSA-N NC(CC(C=C1)=CC(F)=C1C1=NC=CC=N1)C(CC(C=C1)=CC(F)=C1C1=NC=CC=N1)N Chemical compound NC(CC(C=C1)=CC(F)=C1C1=NC=CC=N1)C(CC(C=C1)=CC(F)=C1C1=NC=CC=N1)N ZTUPEBIWNAMBGP-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical class [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108090000925 TNF receptor-associated factor 2 Proteins 0.000 description 1
- 102000004393 TNF receptor-associated factor 2 Human genes 0.000 description 1
- 108090000001 TNF receptor-associated factor 5 Proteins 0.000 description 1
- 102000003718 TNF receptor-associated factor 5 Human genes 0.000 description 1
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 description 1
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004171 alkoxy aryl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical class 0.000 description 1
- 125000005263 alkylenediamine group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000005140 aralkylsulfonyl group Chemical group 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000004090 cyclononenyl group Chemical group C1(=CCCCCCCC1)* 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001945 cyclooctatrienyl group Chemical group C1(=CC=CC=CCC1)* 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- LIWAQLJGPBVORC-UHFFFAOYSA-N ethylmethylamine Chemical compound CCNC LIWAQLJGPBVORC-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical class C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 150000002485 inorganic esters Chemical class 0.000 description 1
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 1
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- QPPQHRDVPBTVEV-UHFFFAOYSA-N isopropyl dihydrogen phosphate Chemical compound CC(C)OP(O)(O)=O QPPQHRDVPBTVEV-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 229950003188 isovaleryl diethylamide Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- NIFHFRBCEUSGEE-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O.OC(=O)C(O)=O NIFHFRBCEUSGEE-UHFFFAOYSA-N 0.000 description 1
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005327 perimidinyl group Chemical group N1C(=NC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 230000004063 proteosomal degradation Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000017702 response to host Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical class [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003459 sulfonic acid esters Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 125000000464 thioxo group Chemical class S=* 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000030829 thyroid gland adenocarcinoma Diseases 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical class OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 125000002114 valyl group Chemical group 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 125000004933 β-carbolinyl group Chemical group C1(=NC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
- C07C211/49—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring having at least two amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C211/54—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
政府支援の承認
一部の実施形態では、本発明の化合物は、式Ia:
X1は、分岐または非分岐C1〜10アルキル、(CH2)s−NH−(CH2)t、(CH2)s−O−(CH2)tまたは(CH2)s−C(NH2)−(CH2)v−NH−(CH2)t(s、tおよびvは、それぞれ独立して、1〜5の整数である)であり;
AおよびBは、それぞれ独立して、C6〜10アリール、C6〜10アリール−C1〜6アルキル、C3〜9ヘテロアリールまたはC3〜9ヘテロアリール−C1〜6アルキルであり、それぞれは、1、2または3個の独立して選択されるRg基で必要に応じて置換されており;
CおよびDは、それぞれ独立して、C3〜7シクロアルキル、C3〜7シクロアルキル−C1〜6アルキル、C3〜7ヘテロシクロアルキル、C3〜7ヘテロシクロアルキル−C1〜6アルキル、C6〜10アリール、C6〜10アリール−C1〜6アルキル、C3〜9ヘテロアリールまたはC3〜9ヘテロアリール−C1〜6アルキルであり、それぞれは、1、2または3個の独立して選択されるRg基で必要に応じて置換されており;
各Rgは独立して、ハロゲン、C1〜6アルキル、C1〜6ハロアルキル、ヒドロキシル、C1〜6アルコキシ、C1〜6ハロアルコキシ、アミノ、C1〜6アルキルアミノまたはジ−C1〜6アルキルアミノであり;
n1およびp1は、それぞれ独立して、1〜10の整数である)
の化合物またはその塩、エステル、溶媒和物、水和物もしくはプロドラッグもまた開示される。
R1およびR2は、それぞれ独立して、C1〜10アルキル、C1〜10アルケニル、C1〜10アルキニル、C3〜7シクロアルキル、C3〜7シクロアルキル−C1〜6アルキル、C3〜7ヘテロシクロアルキルまたはC3〜7ヘテロシクロアルキル−C1〜6アルキルであり、そのそれぞれは、1、2または3個の独立して選択されるRg基で必要に応じて置換されていてもよく;
各Rgは独立して、ハロゲン、C1〜6アルキル、C1〜6ハロアルキル、ヒドロキシル、C1〜6アルコキシ、C1〜6ハロアルコキシ、アミノ、C1〜6アルキルアミノまたはジ−C1〜6アルキルアミノであり;
nおよびpは、それぞれ独立して、1〜10の整数である)
の化合物であり得る。
したがって、実施形態は式Ia:
の化合物を包含する。特定の実施形態では、R5およびR6は、それぞれ独立して、ハロゲンまたはメチルであってよい。一部の実施形態では、式Iaの化合物のフェニル環は、1つのR5、R6またはR5とR6の両方で置換されていてもよく、他の実施形態では、式Iaの化合物は、2つもしくは3つのR5、R6またはR5とR6の両方で置換されていてもよい。
X1は、分岐または非分岐C1〜10アルキル、(CH2)s−NH−(CH2)t、(CH2)s−O−(CH2)tまたは(CH2)s−C(NH2)−(CH2)v−NH−(CH2)t(s、tおよびvは、それぞれ独立して、1〜5の整数である)であり;
AおよびBは、それぞれ独立して、C6〜10アリール、C6〜10アリール−C1〜6アルキル、C3〜9ヘテロアリールまたはC3〜9ヘテロアリール−C1〜6アルキルであり、それぞれは、1、2または3個の独立して選択されるRg基で必要に応じて置換されており;
CおよびDは、それぞれ独立して、C3〜7シクロアルキル、C3〜7シクロアルキル−C1〜6アルキル、C3〜7ヘテロシクロアルキル、C3〜7ヘテロシクロアルキル−C1〜6アルキル、C6〜10アリール、C6〜10アリール−C1〜6アルキル、C3〜9ヘテロアリールまたはC3〜9ヘテロアリール−C1〜6アルキルであり、それぞれは、1、2または3個の独立して選択されるRg基で必要に応じて置換されており;
各Rgは独立して、ハロゲン、C1〜6アルキル、C1〜6ハロアルキル、ヒドロキシル、C1〜6アルコキシ、C1〜6ハロアルコキシ、アミノ、C1〜6アルキルアミノまたはジ−C1〜6アルキルアミノであり;
n1およびp1は、それぞれ独立して、1〜10の整数である)
の化合物またはその塩、エステル、溶媒和物、水和物もしくはプロドラッグを対象とする。
も本明細書において開示されている。ある種の実施形態では、R23〜R30の少なくとも1つはハロゲン、好ましくはフッ素である。特に、R25およびR30はフッ素である。例えば、R25およびR30はフッ素であり、R23、R24、R26、R27、R28およびR29は水素である。ある種の実施形態では、R25はフッ素である。ある種の実施形態では、R26およびR29はフッ素である。例えば、R26およびR29はフッ素であり、R23、R24、R25、R27、R28およびR30は水素である。ある種の実施形態では、n1およびp1はそれぞれ1である。ある種の実施形態では、X1は−CH2CH2−である。ある種の実施形態では、CおよびDは、それぞれ独立して、1、2または3個の独立して選択されるRg基でそれぞれ必要に応じて置換されているピリミジニルである。
も本明細書において開示されている。ある種の実施形態では、R20〜R33の少なくとも1つはハロゲン、好ましくはフッ素である。ある種の実施形態では、R21およびR22はそれぞれフッ素である。
X2は、分岐または非分岐C1〜10アルキル、(CH2)s−NH−(CH2)t、(CH2)s−O−(CH2)tまたは(CH2)s−C(NH2)−(CH2)v−NH−(CH2)t(s、tおよびvは、それぞれ独立して、1〜5の整数である)であり;
A2およびB2は、それぞれ独立して、C6〜10アリール、C6〜10アリール−C1〜6アルキル、C3〜9ヘテロアリールまたはC3〜9ヘテロアリール−C1〜6アルキルであり、それぞれは、1、2または3個の独立して選択されるRg基で必要に応じて置換されており;
R1aおよびR2aは、それぞれ独立して、C1〜10アルキル、C1〜10アルケニル、C1〜10アルキニル、C3〜7シクロアルキル、C3〜7シクロアルキル−C1〜6アルキル、C3〜7ヘテロシクロアルキルまたはC3〜7ヘテロシクロアルキル−C1〜6アルキルであり、そのそれぞれは、1、2または3個の独立して選択されるRg基で必要に応じて置換されていてもよく;
各Rgは独立して、ハロゲン、C1〜6アルキル、C1〜6ハロアルキル、ヒドロキシル、C1〜6アルコキシ、C1〜6ハロアルコキシ、アミノ、C1〜6アルキルアミノまたはジ−C1〜6アルキルアミノであり;
n2およびp2は、それぞれ独立して、1〜10の整数である)
の化合物またはその塩、エステル、溶媒和物、水和物もしくはプロドラッグに方向付けられる。
1.一般式I:
X1は、分岐または非分岐C1〜10アルキル、(CH2)s−NH−(CH2)t、(CH2)s−O−(CH2)tまたは(CH2)s−C(NH2)−(CH2)v−NH−(CH2)t(s、tおよびvは、それぞれ独立して、1〜5の整数である)であり;
AおよびBは、それぞれ独立して、C6〜10アリール、C6〜10アリール−C1〜6アルキル、C3〜9ヘテロアリールまたはC3〜9ヘテロアリール−C1〜6アルキルであり、それぞれは、1、2または3個の独立して選択されるRg基で必要に応じて置換されており;
CおよびDは、それぞれ独立して、C3〜7シクロアルキル、C3〜7シクロアルキル−C1〜6アルキル、C3〜7ヘテロシクロアルキル、C3〜7ヘテロシクロアルキル−C1〜6アルキル、C6〜10アリール、C6〜10アリール−C1〜6アルキル、C3〜9ヘテロアリールまたはC3〜9ヘテロアリール−C1〜6アルキルであり、それぞれは、1、2または3個の独立して選択されるRg基で必要に応じて置換されており;
各Rgは独立して、ハロゲン、C1〜6アルキル、C1〜6ハロアルキル、ヒドロキシル、C1〜6アルコキシ、C1〜6ハロアルコキシ、アミノ、C1〜6アルキルアミノまたはジ−C1〜6アルキルアミノであり;
n1およびp1は、それぞれ独立して、1〜10の整数である)
の化合物またはその塩、エステル、溶媒和物、水和物もしくはプロドラッグ。
X2は、分岐または非分岐C1〜10アルキル、(CH2)s−NH−(CH2)t、(CH2)s−O−(CH2)tまたは(CH2)s−C(NH2)−(CH2)v−NH−(CH2)t(s、tおよびvは、それぞれ独立して、1〜5の整数である)であり;
A2およびB2は、それぞれ独立して、C6〜10アリール、C6〜10アリール−C1〜6アルキル、C3〜9ヘテロアリールまたはC3〜9ヘテロアリール−C1〜6アルキルであり、それぞれは、1、2または3個の独立して選択されるRg基で必要に応じて置換されており;
R1aおよびR2aは、それぞれ独立して、C1〜10アルキル、C1〜10アルケニル、C1〜10アルキニル、C3〜7シクロアルキル、C3〜7シクロアルキル−C1〜6アルキル、C3〜7ヘテロシクロアルキル、またはC3〜7ヘテロシクロアルキル−C1〜6アルキルであり、それぞれは、1、2または3個の独立して選択されるRg基で必要に応じて置換されていてもよく;
各Rgは独立して、ハロゲン、C1〜6アルキル、C1〜6ハロアルキル、ヒドロキシル、C1〜6アルコキシ、C1〜6ハロアルコキシ、アミノ、C1〜6アルキルアミノまたはジ−C1〜6アルキルアミノであり;
n2およびp2は、それぞれ独立して、1〜10の整数である)
の化合物またはその塩、エステル、溶媒和物、水和物もしくはプロドラッグもまた開示される。
(実施例1)
化合物合成
(実施例2)
N1,N2−ビス(3−フルオロ−4−(ピリミジン−2−イル)ベンジル)エタン−1,2−ジアミン(BC−1421)の合成
DME/H2O(1:1、20mL)中の2−クロロピリミジン(572.5mg、5.0mmol)、(2−フルオロ−4−ホルミルフェニル)ボロン酸(839.5mg、5.0mmol)、CsF(1.52g、10mmol)およびPd(PPh3)2Cl2(350mg、0.5mmol)の混合物を、封管中130〜140℃(油浴)で1時間加熱した。これは、懸濁液からほぼ溶液まで変化を受け、懸濁液に戻った。室温に冷却した後、反応物を酢酸エチル(50mL)で希釈し、真空濾過した。固体を酢酸エチル(5mL)で洗浄した。濾過物を酢酸エチル(100mL)で抽出した。有機層を水(30mL)、ブライン(30mL)で洗浄し、無水硫酸ナトリウムで脱水した。真空下で溶媒を除去して、粗生成物を淡褐色固体として得た。これを、フラッシュカラム(シリカゲル、ヘキサン/酢酸エチル、3:1、v/v)で精製して中間体1を白色固体(0.7g、69%収率)として得た。
中間体1(677mg、3.35mmol)とエタン−1,2−ジアミン(100.7mg、1.68mmol)の混合物を、1滴の氷酢酸を含む無水エタノール(15ml)中、還流下で加熱した。反応が完了した後、混合物を室温に冷却した。固体を真空濾過により収集し、乾燥させて中間体2を白色固体(0.64g、89%収率)として得た。
メタノール(10mL)中の中間体2(0.64g、1.5mmol)の懸濁液に、固体NaBH4(113.5mg、3.0mmol)を加えた。反応物を還流下で加熱した。約10分後、これは澄明な溶液に変わった。固体NaBH4(50mg)の追加の部分を加え、反応物を還流下で完了するまで加熱した。室温に冷却した後、これを真空下で濃縮した。残留物を水(25mL)と混合し、酢酸エチル(50mL×2)で抽出した。有機層を水(25mL×2)で洗浄し、無水硫酸ナトリウムで脱水した。溶媒を真空下で除去して粗生成物を淡黄色油状物として得て、これをフラッシュカラム(シリカゲル、トルエン/2−プロパノール/NH4OH=79:20:1、v/v/v)で精製してBC−1421を澄明な油状物として得た。これを、ジクロロメタン(1mL)に溶解し、緩やかに窒素を吹きつけることで蒸発させて固体を得た。高真空下で乾燥させた後、純粋なBC−1421(219.5mg、34%収率)を得た。1H NMR (400 MHz, DMSO−d6) δ 8.91 (d, 4H), 7.94 (t, 2H), 7.46 (t, 2H), 7.30 (m, 4H), 3.75 (s, 4H), 2.61 (s, 4H); LCMS m/z 433.1 [M+H]+, 217.1 [M+2H]2+/2.
250mLの3ツ口丸底フラスコ中の2−クロロ−5−フルオロピリミジン(789mg、5.95mmol)、(2−フルオロ−4−ホルミルフェニル)ボロン酸(1.0g、5.95mmol)、炭酸カリウム(1.65g、11.9mmol)、アセトニトリル(30mL)および水(30mL)の混合物を、窒素を吹き込むことにより15分間脱気し、続いてPd(Ph3)2Cl2(209mg、0.298mmol)を加えた。反応物を還流下で5時間加熱した。室温に冷却した後、これを真空下で濃縮してアセトニトリルを除去した。水溶液中に形成された褐色固体を真空濾過により収集し、水で洗浄し乾燥させた。これを、フラッシュカラム(シリカゲル、ヘキサン/酢酸エチル3:1、v/v)で精製して中間体3をオフホワイト固体(1.0g、77%収率)として得た。
1滴の氷酢酸を含む無水エタノール(5mL)中の中間体3(0.40g、1.82mmol)および(S)−tert−ブチル(2−アミノプロピル)カルバメート(中間体4、0.32g、1.82mmol、文献:Pittelkow, Mら、Synthesis2002年、2195〜2202頁にしたがって調製した)の混合物を還流下で2時間加熱した。室温に冷却した後、溶媒を真空下で除去した。残留物をメタノール(10mL)に溶解し、氷水浴中で冷却し、固体水素化ホウ素ナトリウム(173mg、4.57mmol)で20分間処理した。これを、水(20mL)の添加によりクエンチした。混合物を酢酸エチル(25mL×3)で抽出した。有機層を無水硫酸ナトリウムで脱水した。真空下で溶媒を除去して粗製物を得、これをフラッシュカラム(シリカゲル、ジクロロメタン/メタノール/NH4OH=97:3;0.1)で精製して中間体6を油状物(0.5g)として得た。
中間体6(0.5g)をジクロロメタン(5mL)に溶解し、TFA(5mL)で、室温で1時間処理した。これを真空下で濃縮した。残留物を2N HCl(10mL)に溶解し、ジクロロメタン(20mL×2)で洗浄した。水性相を10N NaOHでpH14に塩基性化し、ジクロロメタン(25mL×5)で抽出した。有機層を無水硫酸ナトリウムで脱水した。真空下で溶媒を除去して中間体7を油状物(0.4g)として得た。
2滴の氷酢酸を含む無水エタノール(10mL)中の中間体7(0.4g、1.44mmol)および4−(5−メチル−1,3,4−オキサジアゾール−2−イル)ベンズアルデヒド(250mg、1.33mmol)の混合物を還流下で終夜加熱した。室温に冷却した後、これを真空下で濃縮した。残留物をメタノール(10mL)に溶解し、氷水浴中で冷却し、固体水素化ホウ素ナトリウム(74mg、1.96mmol)で10分間処理した。これを水(5mL)でクエンチし、ジクロロメタン(50mL×2)で抽出した。有機層を無水硫酸ナトリウムで脱水した。真空下で溶媒を除去して粗製物を得、これをフラッシュカラム(シリカゲル、ジクロロメタン/MeOH/NH4OH=97:3:0.1)で精製して淡黄色油状物(約300mg)を得た。これを1N HCl(10mL)に溶解し、凍結乾燥してオフホワイト粉末を得たが、これは単一の極性不純物(HPLCにより約15%)を含んでいた。この材料を水(70mL)に溶解し、10N NaOHで塩基性化し、ジクロロメタン(50mL×3)で抽出した。有機層を無水硫酸ナトリウムで脱水した。真空下で溶媒を除去して油状物を得た。これを、フラッシュカラム(シリカゲル、ジクロロメタン/MeOH/NH4OH=97:3:0.1)でさらに精製して油状物を得た。これを静置して徐々に固化させて、167.4mgのBC−1568を得た。1H NMR (400 MHz, DMSO−d6) δ 9.00 (s, 2H), 7.90 (m, 3H), 7.50 (m, 2H), 7.30 (m, 2H), 3.60−3.80 (m, 4H), 2.65 (m, 1H), 2.55 (s, 3H), 2.40 (m, 2H), 0.98 (d, 3H); LCMS m/z 451.2 [M+H]+.
ステップ1.アルデヒド中間体8の合成
250mLの3ツ口丸底フラスコ中で2−クロロ−5−フルオロピリミジン(2.65g、20mmol)、(4−ホルミルフェニル)ボロン酸(3.0g、20mmol)、炭酸カリウム(5.53g、40mmol)、アセトニトリル(100mL)および水(100mL)の混合物を、窒素を吹き込むことにより15分間脱気し、続いてPd(Ph3)2Cl2(702mg、1.0mmol)を添加した。反応物を還流下で5時間加熱した。室温に冷却した後、これを真空下で濃縮してアセトニトリルを除去した。水溶液中に形成された褐色固体を真空濾過により収集し、水で洗浄し乾燥させた。これを、フラッシュカラム(シリカゲル、ヘキサン/酢酸エチル3:1、v/v)で精製して中間体8をオフホワイト固体(3.76g、93%収率)として得た。
5滴の氷酢酸を含む無水エタノール(50mL)中の中間体8(2.40g、11.87mmol)および(S)−tert−ブチル(2−アミノプロピル)カルバメート(中間体4、2.07g、11.87mmol)の混合物を還流下で2時間加熱した。室温に冷却した後、溶媒を真空下で除去した。残留物をメタノール(100mL)に溶解し、氷水浴中で冷却し、固体水素化ホウ素ナトリウム(449mg、11.87mmol)で10分間処理した。これを、水(50mL)の添加によりクエンチした。混合物を酢酸エチル(80mL×3)で抽出した。有機層をブライン(50mL)で洗浄し、無水硫酸ナトリウムで脱水した。真空下で溶媒を除去して粗製物を褐色の油状物として得、これをフラッシュカラム(シリカゲル、ジクロロメタン/メタノール/NH4OH=97:3;0.1)で精製して中間体10を淡褐色油状物(2.1g、49%収率)として得た。
中間体10(2.1g)を0℃でジクロロメタン(25mL)に溶解し、続いてTFA(10mL)を添加した。反応物を室温で40分間撹拌した。これを真空下で濃縮して乾燥させた。残留物を、粘性油状物が得られるまで空気を吹きつけることでさらに乾燥させた。この時点でTFA臭がもはや検出されなかった。残留物を水(20mL)中で摩砕(triturate)して黄褐色固体を得た。これを濾過し、水で洗浄し乾燥させて生成物の第1の収量(1.08g)を得た。濾液を凍結乾燥して生成物の第2の収量を白色固体(1.7g)として得た。
無水エタノール(5mL)中の中間体11(342mg、0.7mmol)および酢酸カリウム(151mg、1.54mmol)の混合物を80℃で5分間撹拌し、続いて4−(オキサゾール−5−イル)ベンズアルデヒド(131mg、0.756mmol)を添加した。反応物を還流下で1時間加熱した。これを真空下で濃縮して淡褐色固体を得、これをメタノール(10mL)に溶解した。溶液を氷水浴中で5分間冷却し、続いて固体水素化ホウ素ナトリウム(26.5mg、0.7mmol)を添加した。これを0℃で10分間撹拌し、水(10mL)を添加してクエンチした。メタノールを真空下で除去した。残留物を10N NaOHで塩基性化し、ジクロロメタン(50mL×2)で抽出した。有機層を無水硫酸ナトリウムで脱水した。真空下で溶媒を除去して粗生成物を褐色油状物として得た。これをフラッシュカラム(シリカゲル、ジクロロメタン/メタノール/NH4OH=97:3:0.1)で精製してBC−1563を白色固体(96.4mg、33%収率)として得た。1H NMR (400 MHz, DMSO−d6) δ 8.94 (s, 2H), 8.40 (s, 1H), 8.25 (d, 2H), 7.63 (d, 2H), 7.62 (s, 1H), 7.45 (d, 2H), 7.38 (d, 2H), 3.60−3.80 (m, 4H), 2.70 (m, 1H), 2.40 (m, 2H), 0.98 (d, 3H); LCMS m/z 418.1 [M+H]+.
中間体11を5−(1,3,4−オキサジアゾール−2−イル)ピコリンアルデヒドと反応させることによって、化合物BC−1566を、BC−1563で記載したのと同じ様式で31%の収率で調製した。1H NMR (400 MHz, DMSO−d6) δ 9.39 (s, 1H), 9.06 (s, 1H), 8.94 (s, 2H), 8.32 (d, 1H), 8.23 (d, 2H), 7.64 (d, 1H), 7.46 (d, 2H), 3.60−3.85 (m, 4H), 2.70 (m, 1H), 2.45 (m, 2H), 0.99 (d, 3H); LCMS m/z 420.1 [M+H]+.
中間体11を4−(4−メチルオキサゾール−5−イル)ベンズアルデヒドと反応させることによって、化合物BC−1567を、BC−1563で記載したのと同じ様式で70%の収率で調製した。1H NMR (400 MHz, DMSO−d6) δ 8.94 (s, 2H), 8.29 (s, 1H), 8.24 (d, 2H), 7.52 (d, 2H), 7.45 (d, 2H), 7.39 (d, 2H), 3.60−3.85 (m, 4H), 2.70 (m, 1H), 2.40 (m, 2H), 2.32 (s, 3H), 0.98 (d, 3H); LCMS m/z 432.1 [M+H]+.
無水エタノール(5mL)中の(R)−3,3,3−トリフルオロプロパン−1,2−ジアミン塩酸塩12(271mg、1.65mmol)および酢酸カリウム(178mg、1.82mmol)の混合物を80℃で5分間撹拌し、続いて4−(1,3,4−オキサジアゾール−2−イル)ベンズアルデヒド(287.4mg、1.65mmol)を添加した。反応物を還流下で5時間加熱してやや着色した懸濁液を得た。これを真空下で濃縮した。残留物をメタノール(20mL)に懸濁し、氷水浴中で冷却し、分割(62mg×4)した固体水素化ホウ素ナトリウムで処理した。これを水(20mL)でクエンチし、ジクロロメタン(50mL×3)で抽出した。有機層を無水硫酸ナトリウムで脱水した。真空下で溶媒を除去して淡黄色油状物を得た。これをフラッシュカラム(シリカゲル、酢酸エチル/ヘキサン1:1〜ジクロロメタン/メタノール/NH4OH=97:3:0.1)で精製して中間体13を澄明な油状物として得た。静置すると、これは固化して白色固体(170mg、36%収率)になった。
1滴の氷酢酸を含む無水エタノール(5mL)中の中間体8(113mg、0.56mmol)および中間体13(160mg、0.56mmol)の混合物を還流下で4時間加熱した。これを真空下で濃縮した。残留物を酢酸(5mL)に溶解し、3分割(170mg、33mg、34mg)した固体NaBH(OAc)3で処理した。反応が完了した後、これを水(10mL)で希釈し、10N NaOHでpH4に中和し、ジクロロメタン(50mL×3)で抽出した。有機層を無水硫酸ナトリウムで脱水した。真空下で溶媒を除去して、粗生成物を淡褐色油状物として得た。これを、フラッシュカラム(シリカゲル、ヘキサン/酢酸エチル=3:2)で精製してBC−1564を固体(57.7mg、22%収率)として得た。1H NMR (400 MHz, DMSO−d6) δ 9.31 (s, 1H), 8.94 (s, 2H), 8.25 (d, 2H), 7.91 (d, 2H), 7.47 (d, 4H), 3.90 (m, 2H), 3.69 (s, 2H), 2.60−2.80 (m, 3H); LCMS m/z 473.1 [M+H]+.
Claims (40)
- 式II
X1は、分岐または非分岐C1〜10アルキル、(CH2)s−NH−(CH2)t、(CH2)s−O−(CH2)tまたは(CH2)s−C(NH2)−(CH2)v−NH−(CH2)t(s、tおよびvは、それぞれ独立して、1〜5の整数である)であり;
AおよびBは、それぞれ独立して、C6〜10アリール、C6〜10アリール−C1〜6アルキル、C3〜9ヘテロアリールまたはC3〜9ヘテロアリール−C1〜6アルキルであり、それぞれは、1、2または3個の独立して選択されるRg基で必要に応じて置換されており;
CおよびDは、それぞれ独立して、C3〜7シクロアルキル、C3〜7シクロアルキル−C1〜6アルキル、C3〜7ヘテロシクロアルキル、C3〜7ヘテロシクロアルキル−C1〜6アルキル、C6〜10アリール、C6〜10アリール−C1〜6アルキル、C3〜9ヘテロアリールまたはC3〜9ヘテロアリール−C1〜6アルキルであり、それぞれは、1、2または3個の独立して選択されるRg基で必要に応じて置換されており;
各Rgは独立して、ハロゲン、C1〜6アルキル、C1〜6ハロアルキル、ヒドロキシル、C1〜6アルコキシ、C1〜6ハロアルコキシ、アミノ、C1〜6アルキルアミノまたはジ−C1〜6アルキルアミノであり;
n1およびp1は、それぞれ独立して、1〜10の整数である)
の化合物またはその塩、エステル、溶媒和物、水和物もしくはプロドラッグ。 - AおよびBがそれぞれフェニルであり、それぞれが、1、2または3個の独立して選択されるRg基で必要に応じて置換されている、請求項1に記載の化合物。
- AおよびBがそれぞれフェニルであり、それぞれが、1、2または3個の独立して選択されるRg基で置換されており、Rgがハロゲンである、請求項1に記載の化合物。
- Rgがフッ素である、請求項3に記載の化合物。
- AおよびBが、それぞれ、1個の独立して選択されるRg基で置換されている、請求項3または4に記載の化合物。
- CおよびDが、それぞれ独立してC3〜9ヘテロアリールであり、それぞれが、1、2または3個の独立して選択されるRg基で必要に応じて置換されている、請求項1から5のいずれか一項に記載の化合物。
- CおよびDが、それぞれ独立して、ピリミジニルであり、それぞれが、1、2または3個の独立して選択されるRg基で必要に応じて置換されている、請求項1から5のいずれか一項に記載の化合物。
- CおよびDが、それぞれ独立して、1、2または3個の独立して選択されるRg基で置換されており、Rgはハロゲンである、請求項6または7のいずれか一項に記載の化合物。
- 以下の構造:
を有する、請求項1に記載の化合物。 - R23〜R30の少なくとも1つが、ハロゲン、好ましくはフッ素である、請求項9に記載の化合物。
- R25およびR30がフッ素である、請求項10に記載の化合物。
- 以下の構造:
を有する、請求項1に記載の化合物。 - R20〜R33の少なくとも1つが、ハロゲン、好ましくはフッ素である、請求項12に記載の化合物。
- 以下の構造:
- 式III
X2は、分岐または非分岐C1〜10アルキル、(CH2)s−NH−(CH2)t、(CH2)s−O−(CH2)tまたは(CH2)s−C(NH2)−(CH2)v−NH−(CH2)t(s、tおよびvは、それぞれ独立して、1〜5の整数である)であり;
A2およびB2は、それぞれ独立して、C6〜10アリール、C6〜10アリール−C1〜6アルキル、C3〜9ヘテロアリールまたはC3〜9ヘテロアリール−C1〜6アルキルであり、それぞれは、1、2または3個の独立して選択されるRg基で必要に応じて置換されており;
R1aおよびR2aは、それぞれ独立して、C1〜10アルキル、C1〜10アルケニル、C1〜10アルキニル、C3〜7シクロアルキル、C3〜7シクロアルキル−C1〜6アルキル、C3〜7ヘテロシクロアルキルまたはC3〜7ヘテロシクロアルキル−C1〜6アルキルであり、そのそれぞれは、1、2または3個の独立して選択されるRg基で必要に応じて置換されていてもよく;
各Rgは独立して、ハロゲン、C1〜6アルキル、C1〜6ハロアルキル、ヒドロキシル、C1〜6アルコキシ、C1〜6ハロアルコキシ、アミノ、C1〜6アルキルアミノまたはジ−C1〜6アルキルアミノであり;
n2およびp2は、それぞれ独立して、1〜10の整数である)
の化合物またはその塩、エステル、溶媒和物、水和物もしくはプロドラッグ。 - 一般式I
Xは、C1〜10アルキル、(CH2)s−NH−(CH2)t、(CH2)s−O−(CH2)tまたは(CH2)s−C(NH2)(CH2)v−NH−(CH2)t(s、tおよびvは、それぞれ独立して、1〜5の整数である)であり;
R1およびR2は、それぞれ独立して、アミン、C1〜10アルキル、C1〜10アルケニル、C1〜10アルキニル、C3〜7シクロアルキル、C3〜7シクロアルキル−C1〜6アルキル、C3〜7ヘテロシクロアルキルまたはC3〜7ヘテロシクロアルキル−C1〜6アルキルであり;
nおよびpは、それぞれ独立して、1〜10の整数である)
の化合物またはその塩、エステル、溶媒和物、水和物もしくはプロドラッグ。 - R1とR2が同一である、請求項16に記載の化合物。
- R1およびR2がパラ配置にある、請求項16に記載の化合物。
- 式Ia:
Xは、C1〜10アルキル、(CH2)s−NH−(CH2)t、(CH2)s−O−(CH2)tまたは(CH2)s−C(NH2)−(CH2)v−NH−(CH2)t(s、tおよびvは、それぞれ独立して、1〜5の整数である)であり;
R1およびR2は、それぞれ独立して、アミン、C1〜10アルキル、C1〜10アルケニル、C1〜10アルキニル、C3〜7シクロアルキル、C3〜7シクロアルキル−C1〜6アルキル、C3〜7ヘテロシクロアルキルまたはC3〜7ヘテロシクロアルキル−C1〜6アルキルであり;
nおよびpは、それぞれ独立して、1〜10の整数であり;
R5およびR6は、それぞれ独立して、ハロゲン、C1〜6アルキル、C1〜6ハロアルキル、ヒドロキシル、C1〜6アルコキシ、C1〜6ハロアルコキシ、アミノ、C1〜6アルキルアミノおよびジ−C1〜6アルキルアミノからなる群から選択される)
の化合物である、請求項16に記載の化合物。 - 請求項1から19のいずれか一項に記載の化合物;および
薬学的に許容される担体、添加剤または賦形剤
を含む医薬組成物。 - 前記担体が、担体の水、エタノール、ポリオール、グリセロール、プロピレングリコール、液体ポリエチレングリコール、植物油、堅果油およびその混合物からなる群から選択される、請求項20に記載の医薬組成物。
- 少なくとも1つの香味剤、結合剤、滑沢剤、崩壊剤、表面改質剤、界面活性剤、懸濁化剤、安定化剤、充填剤、流動促進剤、圧縮助剤、崩壊化剤、カプセル化材料またはそれらの組合せをさらに含む、請求項20に記載の医薬組成物。
- 少なくとも1つの抗炎症剤、抗微生物剤、マトリックスメタロプロテアーゼ阻害剤、リポキシゲナーゼ阻害剤、サイトカインアンタゴニスト、免疫抑制剤、抗がん剤、抗ウイルス剤、サイトカイン、成長因子、免疫調節剤、プロスタグランジン、抗血管過剰増殖化合物およびそれらの組合せをさらに含む、請求項20に記載の医薬組成物。
- 前記式Iの化合物またはその塩、エステル、溶媒和物、水和物もしくはプロドラッグが、前記医薬組成物の総重量の約15wt%〜約95wt%を構成する、請求項20に記載の医薬組成物。
- 前記医薬組成物が単位用量形態である、請求項20に記載の医薬組成物。
- 疾患または状態を処置する方法であって:
処置を必要とする患者に請求項20から25のいずれか一項に記載の医薬組成物を投与するステップを含む方法。 - 前記医薬組成物を有効量で投与する、請求項26に記載の方法。
- 疾患または状態を処置する方法であって:
処置を必要とする患者に請求項1から19のいずれか一項に記載の化合物を投与するステップを含む方法。 - 前記化合物が治療有効量で投与される、請求項28に記載の方法。
- 投与するステップが、経口投与、植込みによる投与、非経口注射、静脈注射、腹腔内注射、皮下注射、ボーラス投与、注入、経直腸投与、経膣投与、経皮投与、吸入およびそれらの組合せを含む、請求項26から29のいずれか一項に記載の方法。
- 少なくとも1つの抗炎症剤、抗微生物剤、マトリックスメタロプロテアーゼ阻害剤、リポキシゲナーゼ阻害剤、サイトカインアンタゴニスト、免疫抑制剤、抗がん剤、抗ウイルス剤、サイトカイン、成長因子、免疫調節剤、プロスタグランジン、抗血管過剰増殖化合物およびそれらの組合せを投与するステップをさらに含む、請求項26から30のいずれか一項に記載の方法。
- 前記疾患または状態が炎症性障害である、請求項26から31のいずれか一項に記載の方法。
- 前記疾患または状態が呼吸器の損傷または疾患である、請求項26から31のいずれか一項に記載の方法。
- 前記炎症性障害が、喘息、慢性閉塞性肺疾患、肺線維症、肺臓炎(過敏性肺臓炎および放射線肺臓炎を含む)、肺炎、嚢胞性線維症、乾癬、関節炎/関節リウマチ、鼻炎、咽頭炎、膀胱炎、前立腺炎、皮膚炎、花粉症を含むアレルギー、腎炎、結膜炎、脳炎、髄膜炎、眼球炎、ブドウ膜炎、胸膜炎、心膜炎、心筋炎、アテローム性動脈硬化症、ヒト免疫不全ウイルス関連炎症、糖尿病、変形性関節症、乾癬性関節炎、炎症性腸疾患(クローン病、潰瘍性大腸炎)/大腸炎、敗血症、血管炎、滑液包炎、結合組織疾患、自己免疫疾患、例えば全身性エリテマトーデス(SLE)、リウマチ性多発筋痛症、強皮症、ウェゲナー肉芽腫症、側頭動脈炎、血管炎、クリオグロブリン血症および多発性硬化症、ウイルスもしくはインフルエンザ誘発性の炎症または浮腫などの急性および慢性炎症性障害である、請求項32に記載の方法。
- 前記炎症性障害が、敗血症、肺炎、インフルエンザ誘発性炎症、浮腫、ニューロパチー、大腸炎、関節炎、クローン病、糖尿病、皮膚、眼および耳の炎症(例えば、乾癬、ブドウ膜炎/眼球炎、外耳炎)、全身性エリテマトーデス(SLE)および全身性エリテマトーデス(SLE)である、請求項32に記載の方法。
- 前記疾患または状態が、例えば、マラリア、中毒性肺曝露、がん、アルツハイマー病または熱傷関連損傷などのFBXO3媒介性の障害または損傷である、請求項26から31のいずれか一項に記載の方法。
- 前記呼吸器の損傷または疾患が、急性または慢性の気管支炎、肺気腫、呼吸器感染症(肺炎、胸膜炎)、ウイルス性疾患(インフルエンザを含む)、急性および慢性拒絶反応を含む肺移植後拒絶反応および閉塞性細気管支炎、急性肺損傷もしくは急性呼吸促迫症候群、肺線維症、喘息、嚢胞性線維症または気管支拡張症である、請求項33に記載の方法。
- 請求項1から14のいずれか一項に記載の化合物を患者に投与する、請求項37に記載の方法。
- 前記呼吸器の損傷または疾患が急性または慢性気管支炎である、請求項38に記載の方法。
- 前記呼吸器の損傷または疾患が急性または慢性気管支炎であり、請求項14に記載の化合物を患者に投与する、請求項38に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462090309P | 2014-12-10 | 2014-12-10 | |
US62/090,309 | 2014-12-10 | ||
PCT/US2015/065000 WO2016094659A1 (en) | 2014-12-10 | 2015-12-10 | Compositions and methods for treating diseases and conditions |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017537125A true JP2017537125A (ja) | 2017-12-14 |
JP2017537125A5 JP2017537125A5 (ja) | 2019-01-24 |
JP6906444B2 JP6906444B2 (ja) | 2021-07-21 |
Family
ID=56108183
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017530689A Active JP6906444B2 (ja) | 2014-12-10 | 2015-12-10 | 疾患および状態を処置するための組成物および方法 |
Country Status (12)
Country | Link |
---|---|
US (2) | US10487076B2 (ja) |
EP (1) | EP3230254B1 (ja) |
JP (1) | JP6906444B2 (ja) |
CN (1) | CN107207407B (ja) |
AU (1) | AU2015360482B2 (ja) |
BR (1) | BR112017012303B1 (ja) |
CA (1) | CA3006541C (ja) |
HK (1) | HK1244782A1 (ja) |
IL (1) | IL252707B (ja) |
RU (1) | RU2713886C2 (ja) |
SG (1) | SG11201810861PA (ja) |
WO (1) | WO2016094659A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112014030720A8 (pt) * | 2012-06-08 | 2021-06-22 | The Us Gov As Represented By The Department Of Veterans Affairs | composto, composição farmacêutica e usos de inibidores de fbx03 |
GB202006080D0 (en) * | 2020-04-24 | 2020-06-10 | Univ Greenwich | Cytokine storm syndrome |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2438288A1 (de) | 1974-08-09 | 1976-02-19 | Knoll Ag | Neue antiarrhythmika |
US20030013772A1 (en) | 2000-02-23 | 2003-01-16 | Murphy Michael A. | Composition, synthesis and therapeutic applications of polyamines |
US6221914B1 (en) | 1997-11-10 | 2001-04-24 | Array Biopharma Inc. | Sulfonamide bridging compounds that inhibit tryptase activity |
ATE308515T1 (de) * | 1999-02-05 | 2005-11-15 | Oridigm Corp | Antizymmodulatoren sowie deren verwendung |
US6867299B2 (en) | 2000-02-24 | 2005-03-15 | Hoffmann-La Roche Inc. | Oxamide IMPDH inhibitors |
ATE327973T1 (de) * | 2000-03-24 | 2006-06-15 | Mediquest Therapeutics Inc | Polyamin-analoge als cytotoxische wirkstoffe |
JP2001278869A (ja) | 2000-03-31 | 2001-10-10 | Chemiprokasei Kaisha Ltd | 1,4−ビス(2h−ベンゾトリアゾリル)ピペラジン誘導体、その製造法及び用途 |
US7456222B2 (en) | 2002-05-17 | 2008-11-25 | Sequella, Inc. | Anti tubercular drug: compositions and methods |
US20040033986A1 (en) | 2002-05-17 | 2004-02-19 | Protopopova Marina Nikolaevna | Anti tubercular drug: compositions and methods |
CN101405285B (zh) * | 2006-03-22 | 2012-10-10 | 詹森药业有限公司 | 作为mdm2和p53间相互作用的抑制剂的环状-烷基胺衍生物 |
EP2465856A3 (en) | 2006-08-31 | 2012-12-12 | Abbott Laboratories | Cytochrome P450 oxidase inhibitors and uses thereof |
WO2008142623A2 (en) * | 2007-05-17 | 2008-11-27 | Piramal Life Sciences Limited | Tumor necrosis factor - alpha inhibitors |
GB0903165D0 (en) * | 2009-02-25 | 2009-04-08 | Innospec Ltd | Methods and uses relating to fuel compositions |
US9003827B2 (en) * | 2009-12-18 | 2015-04-14 | Danfoss A/S | Expansion unit for a vapour compression system |
BR112014030720A8 (pt) | 2012-06-08 | 2021-06-22 | The Us Gov As Represented By The Department Of Veterans Affairs | composto, composição farmacêutica e usos de inibidores de fbx03 |
WO2015089087A1 (en) * | 2013-12-09 | 2015-06-18 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Compositions and methods for treating respiratory injury or disease |
-
2015
- 2015-12-10 WO PCT/US2015/065000 patent/WO2016094659A1/en active Application Filing
- 2015-12-10 BR BR112017012303-7A patent/BR112017012303B1/pt not_active IP Right Cessation
- 2015-12-10 JP JP2017530689A patent/JP6906444B2/ja active Active
- 2015-12-10 EP EP15867872.2A patent/EP3230254B1/en active Active
- 2015-12-10 SG SG11201810861PA patent/SG11201810861PA/en unknown
- 2015-12-10 US US15/533,978 patent/US10487076B2/en active Active
- 2015-12-10 CA CA3006541A patent/CA3006541C/en active Active
- 2015-12-10 RU RU2017123927A patent/RU2713886C2/ru active
- 2015-12-10 CN CN201580075792.1A patent/CN107207407B/zh not_active Expired - Fee Related
- 2015-12-10 AU AU2015360482A patent/AU2015360482B2/en not_active Ceased
-
2017
- 2017-06-06 IL IL252707A patent/IL252707B/en active IP Right Grant
-
2018
- 2018-03-26 HK HK18104122.3A patent/HK1244782A1/zh unknown
-
2019
- 2019-10-11 US US16/600,248 patent/US11072606B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
IL252707A0 (en) | 2017-08-31 |
RU2017123927A3 (ja) | 2019-07-17 |
CN107207407A (zh) | 2017-09-26 |
RU2713886C2 (ru) | 2020-02-10 |
EP3230254A1 (en) | 2017-10-18 |
EP3230254B1 (en) | 2021-09-22 |
CA3006541A1 (en) | 2016-06-16 |
EP3230254A4 (en) | 2018-07-25 |
US10487076B2 (en) | 2019-11-26 |
HK1244782A1 (zh) | 2018-08-17 |
JP6906444B2 (ja) | 2021-07-21 |
US20200087294A1 (en) | 2020-03-19 |
RU2017123927A (ru) | 2019-01-10 |
US20180134693A1 (en) | 2018-05-17 |
AU2015360482A1 (en) | 2017-07-13 |
US11072606B2 (en) | 2021-07-27 |
BR112017012303B1 (pt) | 2022-05-24 |
CA3006541C (en) | 2023-06-20 |
BR112017012303A2 (pt) | 2018-06-19 |
CN107207407B (zh) | 2020-12-01 |
IL252707B (en) | 2020-01-30 |
AU2015360482B2 (en) | 2020-07-02 |
SG11201810861PA (en) | 2019-01-30 |
WO2016094659A1 (en) | 2016-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6564380B2 (ja) | 前立腺癌を治療するための化合物 | |
US10226452B2 (en) | Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments | |
JP2010505810A (ja) | アドレナリン作動薬およびムスカリン拮抗薬としてのスルホンアミド誘導体 | |
ES2953474T3 (es) | Nuevas quinazolinonas que inhiben la formación de oligómeros de tau y su modo de uso | |
BRPI0618752A2 (pt) | derivados de pirimidona bicìclica substituìda | |
JP6046149B2 (ja) | H3受容体阻害剤としてのピペリジン及びピペラジン環を含むカルバメート/尿素誘導体 | |
KR20210145166A (ko) | 하전된 이온 채널 차단제 및 사용 방법 | |
CN105682655A (zh) | 抗微生物化合物 | |
BRPI0718519A2 (pt) | 8-piperidinil-2-pridinil-pirimido-[1,2-a]piridimin-6-ona substituída e derivados da 8-piperidinil-2-pirimidinil-pirimido[1,2-a]pirimidin-6-ona | |
US11072606B2 (en) | Compositions and methods for treating diseases and conditions | |
JP2023182589A (ja) | フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用 | |
CA2808582A1 (en) | Imidamide sphingosine kinase inhibitors | |
CN106660968B (zh) | 吡唑衍生物及其作为大麻素受体介体的用途 | |
US10092526B2 (en) | Compositions and methods for treating respiratory injury or disease | |
ES2621901T3 (es) | Derivados de piperazinil pirimidinas, método de preparación y su uso | |
EP3625230A1 (en) | Prodrugs for the treatment of disease | |
JP5931929B2 (ja) | カテプシンc阻害剤 | |
US20200385400A1 (en) | Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | |
TWI821343B (zh) | 流感病毒複製之抑制劑 | |
TW202410897A (zh) | 聯芳醚脲化合物 | |
TW201929847A (zh) | 包含二羧酸之醫藥組合物及其治療應用 | |
JP2024520758A (ja) | Ttbk1の阻害剤 | |
EP4077342A1 (en) | Phosphate derivatives of rorgamma modulators and uses thereof | |
KR20230118970A (ko) | 치환된 시클로헥산카복스아마이드, 이의 제조 방법및 이의 치료적 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181205 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181205 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190829 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190909 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200306 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200615 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200914 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201104 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210402 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210602 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210629 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6906444 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |